Attenuation of brain damage and cognitive impairment by direct renin inhibition in mice with chronic cerebral hypoperfusion

Hypertension

Volumn 58, Issue 4, 2011, Pages 635-642

  Dong, Yi Fei ^a   Kataoka, Keiichiro ^a   Toyama, Kensuke ^a   Sueta, Daisuke ^a   Koibuchi, Nobutaka ^a   Yamamoto, Eiichiro ^a   Yata, Kenichiro ^b   Tomimoto, Hidekazu ^b   Ogawa, Hisao ^a   Kim Mitsuyama, Shokei ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b MIE UNIVERSITY   (Japan)

Author keywords

chronic cerebral ischemia; oxidative stress; renin; vascular dementia; white matter lesion; working memory

Indexed keywords

ALISKIREN; ANGIOTENSINOGEN; PROTEIN P67; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TEMPOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN DAMAGE; BRAIN ISCHEMIA; BRAIN PERFUSION; BRAIN PROTECTION; CAROTID ARTERY OBSTRUCTION; CELL ACTIVATION; CHRONIC DISEASE; COGNITIVE DEFECT; COMMON CAROTID ARTERY; CONTROLLED STUDY; GLIA; MALE; MOUSE; MULTIINFARCT DEMENTIA; NONHUMAN; OXIDATIVE STRESS; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; WHITE MATTER; WORKING MEMORY;

AMIDES; ANGIOTENSINOGEN; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BRAIN DAMAGE, CHRONIC; BRAIN ISCHEMIA; COGNITION DISORDERS; CYCLIC N-OXIDES; DEMENTIA, VASCULAR; DISEASE MODELS, ANIMAL; FUMARATES; HYPERTENSION; MALE; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; RENIN; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SPIN LABELS;

EID: 80053576976     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.173534     Document Type: Article

References (26)

1. Erkinjuntti T, Roman G, Gauthier S, Feldman H, Rockwood K. Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke. 2004;35:1010-1017. (Pubitemid 38419819)
2. Roman GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC. Subcortical ischaemic vascular dementia. Lancet Neurol. 2002;1:426-436. (Pubitemid 37159153)
3. Brown MJ. Aliskiren. Circulation. 2008;118:773-784.
4. Jensen C, Herold P, Brunner HR. Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov. 2008;7:399-410. (Pubitemid 351619112)
5. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007;370: 221-229. (Pubitemid 47069535)
6. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433-2446. (Pubitemid 351793017)
7. McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, Ford J, Verma A, Lewsey J. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008;1:17-24.
8. Dong YF, Liu L, Kataoka K, Nakamura T, Fukuda M, Tokutomi Y, Nako H, Ogawa H, Kim-Mitsuyama S. Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes. Diabetologia. 2010;53:180-191.
9. Dong YF, Liu L, Lai ZF, Yamamoto E, Kataoka K, Nakamura T, Fukuda M, Tokutomi Y, Nako H, Ogawa H, Kim-Mitsuyama S. Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice. J Hypertens. 2010;28:1554-1565.
10. Yamamoto E, Kataoka K, Dong YF, Nakamura T, Fukuda M, Tokutomi Y, Matsuba S, Nako H, Nakagata N, Kaneko T, Ogawa H, Kim-Mitsuyama S. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice. Hypertension. 2009;54:633-638.
11. Shibata M, Ohtani R, Ihara M, Tomimoto H. White matter lesions and glial activation in a novel mouse model of chronic cerebral hypoperfusion. Stroke. 2004;35:2598-2603. (Pubitemid 39458424)
12. Shibata M, Yamasaki N, Miyakawa T, Kalaria RN, Fujita Y, Ohtani R, Ihara M, Takahashi R, Tomimoto H. Selective impairment of working memory in a mouse model of chronic cerebral hypoperfusion. Stroke. 2007;38:2826-2832. (Pubitemid 47494024)
13. Washida K, Ihara M, Nishio K, Fujita Y, Maki T, Yamada M, Takahashi J, Wu X, Kihara T, Ito H, Tomimoto H, Takahashi R. Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator-activated receptor-γactivation in mice with chronic cerebral hypoperfusion. Stroke. 2010;41:1798-1806.
14. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective pparγ-modulating activity. Hypertension. 2004;43:993-1002. (Pubitemid 38579904)
15. Ihara M, Tomimoto H, Kinoshita M, Oh J, Noda M, Wakita H, Akiguchi I, Shibasaki H. Chronic cerebral hypoperfusion induces MMP-2 but not MMP-9 expression in the microglia and vascular endothelium of white matter. J Cereb Blood Flow Metab. 2001;21:828-834. (Pubitemid 32613537)
16. Nakaji K, Ihara M, Takahashi C, Itohara S, Noda M, Takahashi R, Tomimoto H. Matrix metalloproteinase-2 plays a critical role in the pathogenesis of white matter lesions after chronic cerebral hypoperfusion in rodents. Stroke. 2006;37:2816-2823. (Pubitemid 44922545)
17. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87: 245-313. (Pubitemid 46209993)
18. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci. 2004;5:347-360. (Pubitemid 38568496)
19. Infanger DW, Sharma RV, Davisson RL. NADPH oxidases of the brain: distribution, regulation, and function. Antioxid Redox Signal. 2006;8: 1583-1596. (Pubitemid 44726333)
20. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev. 2000;52: 11-34. (Pubitemid 30127593)
21. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000;86:494-501. (Pubitemid 30165039)
22. Iadecola C, Park L, Capone C. Threats to the mind: aging, amyloid, and hypertension. Stroke. 2009;40:S40-S44.
23. Kim-Mitsuyama S, Yamamoto E, Tanaka T, Zhan Y, Izumi Y, Izumiya Y, Ioroi T, Wanibuchi H, Iwao H. Critical role of angiotensin II in excess salt-induced brain oxidative stress of stroke-prone spontaneously hypertensive rats. Stroke. 2005;36:1083-1088.
24. Yamamoto E, Tamamaki N, Nakamura T, Kataoka K, Tokutomi Y, Dong YF, Fukuda M, Matsuba S, Ogawa H, Kim-Mitsuyama S. Excess salt causes cerebral neuronal apoptosis and inflammation in stroke-prone hypertensive rats through angiotensin II-induced NADPH oxidase activation. Stroke. 2008;39:3049-3056.
25. Bright R, Mochly-Rosen D. The role of protein kinase C in cerebral ischemic and reperfusion injury. Stroke. 2005;36:2781-2790.
26. Hewett SJ, Bell SC, Hewett JA. Contributions of cyclooxygenase-2 to neuroplasticity and neuropathology of the central nervous system. Pharmacol Ther. 2006;112:335-357. (Pubitemid 44486408)